

Freedom of Information Request: Our Reference CTHB_392_16

You asked:

Please note that the data provided below relates to Financial Year 15/16. Unfortunately, due to the way the data is processed and monitored within the Health Board, we are unable to provide data that cuts across two financial years as it is not in a readily available format e.g. Q4 requests the last 12 months.

1. What is the Trust's annual spend on anti-TNF drugs (most recent year available)?

Cwm Taf University Health Board's annual spend on anti-TNF drugs for Financial Year 15/16 is £4,006,131.

2. How many patients has the Trust treated with anti-TNF drugs in the last 12 months?

The number of patients treated with Anti-TNF drugs during the Financial Year of 15/16 is 530.

3. What is the % split of anti-TNF patients by the following channels:

The % split of anti-TNF patients by the following channels based on 14/15 data:

Channel	% of Patients
Homecare	86%
Outpatient	14%
Inpatient	

4. How many patients has the Trust treated with the following conditions in last 12 months:

The number of patients Cwm Taf UHB has treated with the following conditions during the financial year 15/16:

Condition	Number of Patients
Rheumatoid Arthritis	244
Crohn's Disease	69
Psoriasis	**
Other anti-TNF Conditions	213

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when

considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 1998, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles set out in Schedules 2 and 3 of the Act. Section 40 is an absolute exemption and does not require the Health Board to consider the public interest test.

5. Are there any gain share agreements in place between the Trust and CCGs for anti-TNF biosimilars?

This question is not applicable to Cwm Taf and NHS Wales, CCGs are part of NHS England.

6. If yes, please provide:

Name of CCG	Name of Specific Drug?	Start Date of Agreement	Length of Agreement	Gain Share Split %

Request for Re-use

Please can you confirm whether we are permitted to reuse any information provided under the Open Government Licence?

You are free to use any information supplied for your own non-commercial research or private study purposes. The information may also be used for any other purpose allowed by a limitation or exception in copyright law, such as news reporting. However, any other type of re-use, for example by publishing the information in analogue or digital form, including on the internet, will require the permission of the copyright owner.